Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Arepanrix (H1N1) in Japanese Children
NCT01001169Phase 2Completed
- Sponsor
- GSK
- Start
- Oct 2009
- Primary completion
- May 2010
- Modality
- Split/Subunit Vaccines, Recombinant Protein Vaccines, Cancer Vaccines
- Countries
- 1
01
Overview
Phase 2, open-label trial of recombinant influenza ha vaccine (h5n1) in influenza (2 arms), sponsored by GSK. Primary endpoints: Number of Subjects With Haemagglutination Inhibition (HI) Antibody Concentrations Above the Cut-off Value at Day 42, Titers for Serum HI Antibodies Against Flu A/CAL/7/09 Strain at Day 42 and 3 more. Started Oct 2009; status: completed.
02
Drugs
recombinant influenza ha vaccine (h5n1)
03
Conditions
influenza
Beyond the preview
Go deeper on NCT01001169.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01001169.